Yanan Zhu
Stock Analyst at Wells Fargo
(2.15)
# 2,903
Out of 4,981 analysts
78
Total ratings
42.86%
Success rate
-3.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.67 | +49.81% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $24.12 | +86.57% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $61.11 | +34.20% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $1.81 | +562.98% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $3.02 | +165.34% | 3 | Aug 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $4 → $2.5 | $0.95 | +163.10% | 4 | Aug 13, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $6 → $5 | $1.32 | +278.79% | 4 | Aug 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $42 | $18.16 | +131.28% | 8 | Aug 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $38 | $17.53 | +116.77% | 5 | Aug 8, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $14 | $2.27 | +516.74% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $11.57 | +289.11% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $40.19 | +86.61% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $50 | $17.48 | +186.06% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $1 | $0.07 | +1,399.25% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $21.24 | +229.64% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.21 | +137.81% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $30 | $14.84 | +102.22% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $14.83 | +169.72% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $57.85 | +12.36% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.71 | +425.39% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.50 | +702.09% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.29 | +19,550.66% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $753.98 | -56.76% | 1 | Feb 2, 2021 |
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.67
Upside: +49.81%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $24.12
Upside: +86.57%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $61.11
Upside: +34.20%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.81
Upside: +562.98%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $3.02
Upside: +165.34%
Fate Therapeutics
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $0.95
Upside: +163.10%
Autolus Therapeutics
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.32
Upside: +278.79%
Arcturus Therapeutics Holdings
Aug 12, 2025
Maintains: Overweight
Price Target: $45 → $42
Current: $18.16
Upside: +131.28%
RAPT Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $51 → $38
Current: $17.53
Upside: +116.77%
Iovance Biotherapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.27
Upside: +516.74%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $11.57
Upside: +289.11%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $40.19
Upside: +86.61%
Aug 7, 2025
Maintains: Overweight
Price Target: $48 → $50
Current: $17.48
Upside: +186.06%
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.07
Upside: +1,399.25%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $21.24
Upside: +229.64%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.21
Upside: +137.81%
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $14.84
Upside: +102.22%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $14.83
Upside: +169.72%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $57.85
Upside: +12.36%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $5.71
Upside: +425.39%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.50
Upside: +702.09%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.29
Upside: +19,550.66%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $753.98
Upside: -56.76%